Align Partners Submits Shareholder Proposals at Coway Co., Ltd. to Protect the Interests of Minority Shareholders
6.2.2025 13:00:00 CET | Business Wire | Press release
Proposals follow Coway’s failure to respond to governance concerns surrounding how the Board manages conflicts of interest with its largest shareholder, Netmarble.Align submitted shareholder proposals to strengthen the independent oversight mechanism at Coway by nominating an independent governance and capital markets expert.To ensure minority shareholder representation is upheld, and meet market best practice, Align is also proposing Coway to introduce cumulative voting.
Align Partners Capital Management Inc. ("Align Partners"), a shareholder of Coway Co., Ltd. ("Coway" or "Company") since 2023, submitted 4 shareholder proposals on February 6, 2025, for the upcoming Annual General Meeting (“AGM”). These proposals aim to ensure that Coway’s governance works for all, and not just its largest shareholder.
More specifically, Align Partners will be seeking support to appoint Namuh Rhee, an independent governance and capital markets expert and Chair of the Korea Corporate Governance Forum, to the Board and Audit Committee. To secure his place, Align Partners will seek to expand the Board to prevent any defensive seat-filling by Coway. Finally, Align Partners aim to protect minority rights by securing approval to introduce cumulative voting, ensuring their voting power serves as a meaningful accountability lever.
Our concerns have been transparent regarding Coway’s governance—concerns that, based on shareholder feedback, are widely shared. To ensure equal access to information, we formally submitted questions to Coway, demanding clarity on fundamental yet critical aspects of its governance framework. TheBoard’s failure to outline a clear framework for mitigating the conflict of interest between its Executive Chair—who also leads Netmarble, Coway’s largest shareholder—and minority shareholders poses a serious governance risk. Given Netmarble’s track record of capital misallocation, these concerns are only further magnified.
All shareholders deserve greater transparency and stronger governance from Coway. We urge shareholders to support our proposals and demand that Coway disclose its “Value-Up Plan" (planned for disclosure sometime Q1 2025) before the AGM, ensuring shareholders can make fully informed decisions at the meeting.
More information can be found in our Presentation available at https://www.bside.ai/coway/feed/1206.
About
Align Partners is a Korea-focused investment firm led by CEO Changhwan Lee, leveraging private equity and investment banking expertise to drive sustainable growth and address the "Korea discount."
https://www.alignpartnerscap.com/en/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250206617823/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press release
Corpay Private Markets publishes its fourth Lender Book Report, drawing on proprietary transaction data and live lender appetite tracking across 500+ lenders Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP
Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch23.4.2026 10:00:00 CEST | Press release
Now with new international vehicle, Pantheon offers clients global evergreen access to full suite of private equity, private credit secondaries, and infrastructure secondaries Pantheon bolsters its globally recognized, specialist approach in infrastructure secondaries in the evergreen market with the launch of the Pantheon Global Infrastructure Secondaries Fund (“PGIS”) PGIS will tap the expertise of Pantheon’s $26.9 billion1 institutional infrastructure franchise Fund marks latest in Pantheon’s growing, $15 billion2 global evergreen platform, which now includes semi-liquid evergreen offerings across private equity, private credit secondaries and infrastructure secondaries in the US and internationally3 Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the exp
KAYTUS Unveils MotusAI Enhancements with OpenClaw for Enterprise-Grade AI Agents23.4.2026 09:02:00 CEST | Press release
Providing a high-availability compute foundation for seamless AI agent deployment, greater resource efficiency, and enterprise-grade reliability. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, today launched new capabilities in its MotusAI AI DevOps platform to accelerate the deployment of enterprise-grade AI agents. By a streamlined three-step integration with the OpenClaw framework, MotusAI provides the compute infrastructure, resource orchestration, and operational support required to address deployment bottlenecks, and enable AI agents to scale from early-stage experimentation to dependable enterprise use. Key Challenge for Enterprise-Grade AI Agents: Guaranteed Reliability and Performance As the AI landscape transitions from chatbots to AI agents, enterprises are facing a fundamental constraint: the value of even the most advanced large language model (LLM) depends on the stability and performance of the underlying execution infrastructure. At presen
Samsung Epis Holdings Reports First Quarter 2026 Financial Results23.4.2026 08:54:00 CEST | Press release
Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.” First Quarter 2026 Results On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KR
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency23.4.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy. Widespread net sales growth of 25.5% year-on-year at constant currency1,aligned with strong growth performance across geographies and product categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%). Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion. Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II results for nemoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom